Prediction markets now allow retail investors to place financial bets on whether pharmaceutical drugs will gain FDA approval, raising alarm among regulators and researchers about potential conflicts of interest in clinical research.
Two platforms, Kalshi and Polymarket, have launched markets where users can wager on drug approval outcomes. Kalshi plans to expand further by permitting bets on clinical trial results themselves, creating financial incentives that extend directly into the research process.
The concern centers on perverse incentives. If researchers or trial participants stand to profit from specific outcomes, the integrity of data collection and reporting becomes compromised. A negative trial result that contradicts investor positions could face pressure or manipulation. Conversely, financial rewards tied to positive findings might discourage rigorous scrutiny of adverse events or safety signals.
The FDA and SEC have not yet formally responded to these markets, but experts warn the regulatory gap creates real problems. Unlike traditional pharmaceutical investment, where wealth flows based on eventual approval decisions, prediction markets place direct financial stakes on the research process itself. This distinction matters enormously. A researcher or trial coordinator with financial exposure could unconsciously bias patient selection, data interpretation, or adverse event reporting.
Clinical trial integrity depends on investigators acting without conflicting financial interests. The Belmont Report and modern research ethics frameworks explicitly prohibit such arrangements. These markets bypass those protections by creating legal betting instruments that monetize research outcomes.
Proponents argue prediction markets simply aggregate information already available to investors through stock trading. Critics counter that direct market access changes the equation fundamentally. Stock investors bet on eventual approval. Prediction market participants can bet on interim results, trial endpoints, and specific regulatory decisions before those outcomes reach public knowledge.
The research community faces a timing problem. Regulatory bodies move slowly, but these platforms operate at market speed. Establishing clear rules around researcher disclosure obligations, betting restrictions, and institutional liability will require coordination between the FDA, SEC, and research